Entrada Therapeutics (TRDA) announced that the United States Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and ...

Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...

Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...

(RTTNews) - Entrada Therapeutics, Inc. (TRDA), a clinical-stage biopharmaceutical company, on Monday provided an update on its upcoming Phase 1/2 clinical trial for ENTR-601-44, a treatment for ...

Entrada Therapeutics' innovative Endosomal Escape Vehicle platform, poised to revolutionize drug delivery. Click here to read ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Entrada Therapeutics CEO Dipal Doshi said: “As the first authorisation for our global MAD clinical study of ENTR-601-44 in patients, we are pleased to be initiating the study at what we believe ...

ENTR-601-44 is a proprietary Endosomal Escape Vehicle (EEV™)-conjugated phosphorodiamidate morpholino oligomer (PMO) designed to restore the mRNA reading frame and allow for the production of a ...

Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with ...